AbbVie added its best-selling cancer medicine Imbruvica to its restrictions on 340B pricing when hospitals use contract pharmacies. The company jointly developed and markets Imbruvica with J&J's Janssen.

AbbVie Adds its Top-Selling Cancer Drug Imbruvica to its 340B Contract Pharmacy Restrictions

Drug manufacturer AbbVie had added its best-selling cancer medicine Imbruvica to its restrictions on 340B pricing when hospitals use contract pharmacies, effective April 1.

AbbVie contractor 340B ESP posted a policy update from AbbVie on its website on March 1. The six-page document appears to be nearly identical to AbbVie’s original late December 2021 notice to covered entities except for two small changes on the last page—Imbruvica’s inclusion on the list of covered products, and a short note below the list stating, “340B Integrity Initiative will become effective for Imbruvica on April 1, 2022.”

Drug manufacturer AbbVie had added its best-selling cancer medicine Imbruvica to its restrictions on 340B pricing when hospitals use contract pharmacies, effective April 1.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report